The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Healthcare leaders, policymakers, hospitals, and patient advocates discuss AI-driven healthcare, digital transformation, quality of life in cancer care
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
The summit will bring together 1,200+ delegates, 100+ international faculty from 25 countries
Multidisciplinary team expansion brings integrated medical, surgical, and radiation oncology services under one roof
New facility offers genetic testing, counselling and personalised treatment plans to enable early diagnosis and precision-led care
The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
